

# **The best shot: reaching 22 million missed children**

**Geoff Adlide, Director Advocacy and Public Policy  
GAVI Alliance**

*A seminar on accelerating access to vaccination*

*Oslo, 14 October 2013*



# Mission and strategic goals 2011–2015

*To save children's lives and protect people's health by increasing access to immunisation in poor countries*


**1** **The vaccine goal**  
Accelerate the uptake and use of underused and new vaccines

**2** **The health systems goal**  
Contribute to strengthening the capacity of integrated health systems to deliver immunisation

**3** **The financing goal**  
Increase the predictability of global financing and improve the sustainability of national financing for immunisation


**4** **The market shaping goal**  
Shape vaccine markets to ensure adequate supply of appropriate, quality vaccines at low and sustainable prices

# GAVI's supply and procurement objectives



# Increased competition reduces vaccine price


Price decline of pentavalent vaccine and number of manufacturers



# Vaccine prices and supply security


As of the end of 2012

**Change in the total cost to fully immunise a child with pentavalent, pneumococcal and rotavirus vaccines**  
Selected vaccine package price (US\$)




\* Future targets are not publicised to avoid setting a minimum price.

**Number of products offered as percentage of 5-year target (%)**




# Pentavalent roadmap



# GAVI's co-financing policy: country ownership and steps to sustainability

- Country groupings:
  - **Low-income** countries (<US\$ 1,025 per capita GNI) pay US\$ 0.20 per dose
  - **Intermediate** countries (US\$ 1,025–US\$ 1,550) increase co-payments by 15% per year
  - **Graduating** countries (>US\$ 1,550) increase payments steadily to reach sustainability after five years

# How the co-financing policy works




Source: GAVI Alliance 2013





# Fiscal space not the main bottleneck to sustain vaccines post-GAVI



Source: GAVI Secretariat with data from GAVI Strategic Demand Forecast; IMF; NHA. See Health Affairs June 2011

A seminar on accelerating access to vaccination  
14 October 2013



Thank you




GAVI/2011/Ed Harris

*A seminar on accelerating access to vaccination  
14 October 2013*



# Tiered pricing




Source: GAVI Alliance, 2012

*A seminar on accelerating access to vaccination  
14 October 2013*



# Co-financing: countries fulfilling commitments



Source: GAVI Alliance data as of 1 September 2013

# Pentavalent Tender

## 10 YEARS OF TURNING UP **THE VOLUME** ON THE PENTAVALENT VACCINE

### LOWER PRICES FOR GAVI COUNTRIES



### HIGHER VOLUME



\*UNITED STATES MARKET PRICE: lowest total public price per dose for separate DTP, hepB and Hib vaccines and reflects the cost of acellular pertussis vaccine. (2013 data)

\*2013 YEAR-END PROJECTION

A seminar on accelerating access to vaccination  
14 October 2013